BIOMAT Database Logo BIOMAT Database Logo

[5-(2-bromovinyl)-2'-deoxyuridine therapy of herpes zoster diseases in patients with malignant primary diseases]. 1988

P Wutzler, and K Wutke, and D Bärwolff, and J Reefschläger
Institut für Medizinische Mikrobiologie, der Medizinischen Akademie Erfurt, DDR.

BVDU [(E)-5-(2-bromovinyl)-2'-deoxyuridine] has proved effective in the treatment of varicella-zoster virus diseases in patients with malignancies. In 13 out of 20 patients a prompt cessation of new vesicle formation accompanied by rapid resolution of fever, crusting and complete epithelialisation of cutaneous lesions were noted. Only in few cases a prolonged recovery from the severe zoster occurred. When starting the treatment later than 48 hours after the onset of initial rash the dissemination of epithelial lesions could not be prevented. BVDU was well tolerated. Laboratory abnormalities were observed only in some cases and did not result in interruption of treatment.

UI MeSH Term Description Entries
D007074 Immunoglobulin G The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B. Gamma Globulin, 7S,IgG,IgG Antibody,Allerglobuline,IgG(T),IgG1,IgG2,IgG2A,IgG2B,IgG3,IgG4,Immunoglobulin GT,Polyglobin,7S Gamma Globulin,Antibody, IgG,GT, Immunoglobulin
D007075 Immunoglobulin M A class of immunoglobulin bearing mu chains (IMMUNOGLOBULIN MU-CHAINS). IgM can fix COMPLEMENT. The name comes from its high molecular weight and originally was called a macroglobulin. Gamma Globulin, 19S,IgM,IgM Antibody,IgM1,IgM2,19S Gamma Globulin,Antibody, IgM
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D009894 Opportunistic Infections An infection caused by an organism which becomes pathogenic under certain conditions, e.g., during immunosuppression. Infection, Opportunistic,Infections, Opportunistic,Opportunistic Infection
D001973 Bromodeoxyuridine A nucleoside that substitutes for thymidine in DNA and thus acts as an antimetabolite. It causes breaks in chromosomes and has been proposed as an antiviral and antineoplastic agent. It has been given orphan drug status for use in the treatment of primary brain tumors. BUdR,BrdU,Bromouracil Deoxyriboside,Broxuridine,5-Bromo-2'-deoxyuridine,5-Bromodeoxyuridine,NSC-38297,5 Bromo 2' deoxyuridine,5 Bromodeoxyuridine,Deoxyriboside, Bromouracil
D005260 Female Females
D006562 Herpes Zoster An acute infectious, usually self-limited, disease believed to represent activation of latent varicella-zoster virus (HERPESVIRUS 3, HUMAN) in those who have been rendered partially immune after a previous attack of CHICKENPOX. It involves the SENSORY GANGLIA and their areas of innervation and is characterized by severe neuralgic pain along the distribution of the affected nerve and crops of clustered vesicles over the area. (From Dorland, 27th ed) Shingles,Zona,Zoster
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

P Wutzler, and K Wutke, and D Bärwolff, and J Reefschläger
Oral (E)-5-(2-bromovinyl)-2'-deoxyuridine in severe herpes zoster.
November 1980, British medical journal,
P Wutzler, and K Wutke, and D Bärwolff, and J Reefschläger
Oral (E)-5-(2-bromovinyl)-2'-deoxyuridine treatment of severe herpes zoster in cancer patients.
April 1984, European journal of cancer & clinical oncology,
P Wutzler, and K Wutke, and D Bärwolff, and J Reefschläger
Therapy of varicella-zoster virus infection--mechanism of action of (E)-5-(2-bromovinyl)-2'-deoxyuridine.
January 1985, Antiviral research,
P Wutzler, and K Wutke, and D Bärwolff, and J Reefschläger
(E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU).
January 2005, Medicinal research reviews,
P Wutzler, and K Wutke, and D Bärwolff, and J Reefschläger
(E)-5-(2-bromovinyl)-2'-Deoxyuridine in the treatment of experimental herpes simplex keratitis.
January 1980, Antimicrobial agents and chemotherapy,
P Wutzler, and K Wutke, and D Bärwolff, and J Reefschläger
(E)-5-(2-Bromovinyl)-2'-deoxyuridine: a potent and selective anti-herpes agent.
June 1979, Proceedings of the National Academy of Sciences of the United States of America,
P Wutzler, and K Wutke, and D Bärwolff, and J Reefschläger
Treatment of experimental herpes simplex virus encephalitis with (E)-5-(2-bromovinyl)-2'-deoxyuridine in mice.
September 1982, Antimicrobial agents and chemotherapy,
P Wutzler, and K Wutke, and D Bärwolff, and J Reefschläger
Bioanalysis of (E)-5-(2-bromovinyl)-2'-deoxyuridine.
June 1988, Journal of chromatography,
P Wutzler, and K Wutke, and D Bärwolff, and J Reefschläger
5 IODO-2'-DEOXYURIDINE IN THE TREATMENT OF HERPES ZOSTER.
November 1964, The British journal of dermatology,
P Wutzler, and K Wutke, and D Bärwolff, and J Reefschläger
Efficacy of (E)-5-(2-bromovinyl)-2'-deoxyuridine in the topical treatment of herpes simplex keratitis.
January 1981, Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie. Albrecht von Graefe's archive for clinical and experimental ophthalmology,
Copied contents to your clipboard!